Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 6.3M | 4724.6% |
| Gross Profit | 6.2M | 4648.5% |
| Cost of Revenue | 99,000 | 65.1% |
| Operating expense | 11M | 10.5% |
| Net Income | -4.7M | 54.2% |
| EBITDA | -5.1M | 59.1% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 77M | 5.2% |
| Total Liabilities | 22M | 3.3% |
| Total Equity | 56M | 5.9% |
| Shares Outstanding | 71M | 0.1% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -4.8M | 53.6% |
| Cash from investing | 12M | 136.2% |
EPS
Financial Highlights for Ovid Therapeutics in Q2 '25
Ovid Therapeutics reported a revenue of 6.3M, which is a 4724.6% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 6.2M, marking a 4648.5% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 99,000, a -65.1% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 11M, showing a -10.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -4.7M, showing a 54.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -5.1M, showing a 59.1% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Ovid Therapeutics with growth in revenue, gross profit, and net income.
